Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Efficacy and safety outcomes of a randomized, multi-center phase II study investigating

Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: A systematic review and meta-analysis

“…27 trials were open-label whereas the only one was double-blind placebo controlled. From the abstracts presented at ASCO meetings, we identified one abstract with full-text publication that was not previously identified in the PubMed [39].…”

Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis

“…According to the inclusion criteria of each trial, patients were required to have adequate hepatic, renal and hematological function. Underlying malignancies included colorectal cancer (eleven trials) [14,15,[22][23][24][25][26][27][28][29][30][31], non-small-cell lung cancer (seven trials) [32][33][34][35][36][37][38], head and neck cancer (four trials) [5,13,39,40], breast cancer (one trial) [41], urothelial carcinoma (one trial) [42], pancreatic cancer (one trial) [43] and esophagogastric cancer (one trial) [44].…”

Synergistic effects of crizotinib and radiotherapy in experimental EML4–ALK fusion positive lung cancer

“…Despite improvements in radiotherapy delivery [1,2] and novel chemotherapy combinations and schemes [3,4], the median survival in this relatively heterogeneous collective population is $21 months with 3 year survival rates of $30% [5,6].…”